Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer
Dana-Farber Cancer Institute · Princess Margaret Cancer Centre · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
629
total citations
- FWCI
- 40.73
- Percentile
- 100%
- References
- 36
Citations per year
Authors
40Topics & keywords
Topics
Keywords
- Bromodomain
- BRD4
- Triple-negative breast cancer
- BET inhibitor
- Chromatin
- Cancer research
- Breast cancer
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- UDU.S. Department of Defense
- SGSusan G. Komen for the Cure
- CPCancer Prevention and Research Institute of TexasAwards: RP140367, RP110471
- DCDana-Farber/Harvard Cancer Center
- PMPrincess Margaret Cancer Foundation
- NINational Institutes of HealthAwards: CA103867, CA080111
- LCLudwig Center at Harvard
- NSNatural Sciences and Engineering Research Council of CanadaAward: RGPIN-2015
- CDCongressionally Directed Medical Research ProgramsAward: CA120184